Literature DB >> 16898908

A prospective evaluation of the cost of psoriasis in Spain (EPIDERMA project: phase II).

J M Carrascosa1, R Pujol, E Daudén, J M Hernanz-Hermosa, X Bordas, J A Smandia, C Ferrándiz.   

Abstract

OBJECTIVE: To estimate the direct and indirect costs related to psoriasis in Spain.
METHODS: We performed a 12-month, multicentre, prospective longitudinal and observational study. Overall expense of care was assessed as the sum of direct and indirect costs.
RESULTS: A total of 797 patients with varying demographics and different degrees of severity of psoriasis were included in the study. The mean total cost of psoriasis, including direct and indirect items, was 1,079 euro per patient and year. The major sources of expenditure were prescription drugs (46.6%), followed by medical activities (34.5%). Mean costs in patients with moderate and severe psoriasis were approximately 1.5 and 2.5 times higher than in those with mild psoriasis, respectively.
CONCLUSIONS: In Spain, psoriasis is associated with substantial costs both to the National Health System and to the patients.

Entities:  

Mesh:

Year:  2006        PMID: 16898908     DOI: 10.1111/j.1468-3083.2006.01659.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  9 in total

Review 1.  The burden of moderate to severe psoriasis: an overview.

Authors:  Giovanna Raho; Daniela Mihajlova Koleva; Livio Garattini; Luigi Naldi
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

2.  Effects of adalimumab versus placebo on risk of symptom worsening in psoriasis and subsequent impacts on health-related quality-of-life: analysis of pooled data from two randomized, double-blind, placebo-controlled, multicentre clinical trials.

Authors:  Kim A Papp; James Signorovitch; Karthik Ramakrishnan; Andrew P Yu; Shiraz R Gupta; Yanjun Bao; Parvez M Mulani
Journal:  Clin Drug Investig       Date:  2011       Impact factor: 2.859

Review 3.  Large-scale, prospective, observational studies in patients with psoriasis and psoriatic arthritis: A systematic and critical review.

Authors:  Sue Langham; Julia Langham; Hans-Peter Goertz; Mark Ratcliffe
Journal:  BMC Med Res Methodol       Date:  2011-03-31       Impact factor: 4.615

4.  The costs of psoriasis medications.

Authors:  Anssi Mustonen; Kalle Mattila; Mauri Leino; Leena Koulu; Risto Tuominen
Journal:  Dermatol Ther (Heidelb)       Date:  2013-12-13

5.  Psoriasis causes significant economic burden to patients.

Authors:  A Mustonen; K Mattila; M Leino; L Koulu; R Tuominen
Journal:  Dermatol Ther (Heidelb)       Date:  2014-05-28

6.  Treatment costs of psoriasis in a tertiary-level clinic.

Authors:  Anssi Mustonen; Mauri Leino; Kalle Mattila; Leena Koulu; Risto Tuominen
Journal:  BMC Health Serv Res       Date:  2014-08-15       Impact factor: 2.655

7.  How much of the productivity losses among psoriasis patients are due to psoriasis.

Authors:  Anssi Mustonen; Kalle Mattila; Mauri Leino; Leena Koulu; Risto Tuominen
Journal:  BMC Health Serv Res       Date:  2015-03-04       Impact factor: 2.655

8.  Determining the Value of Two Biologic Drugs for Chronic Inflammatory Skin Diseases: Results of a Multi-Criteria Decision Analysis.

Authors:  Néboa Zozaya; Lucía Martínez-Galdeano; Bleric Alcalá; Jose Carlos Armario-Hita; Concepción Carmona; Jose Manuel Carrascosa; Pedro Herranz; María Jesús Lamas; Marta Trapero-Bertran; Álvaro Hidalgo-Vega
Journal:  BioDrugs       Date:  2018-06       Impact factor: 5.807

9.  Humanistic and Economic Impact of Moderate to Severe Plaque Psoriasis in Brazil.

Authors:  Nilcéia Lopes; Leticia L S Dias; Luna Azulay-Abulafia; Luiza K M Oyafuso; Maria Victoria Suarez; Lincoln Fabricio; Clarice Marie Kobata; Tania Cestari; Bernardo Gontijo; Cid Y Sabbag; João R Antonio; Ricardo Romiti; Patricia C Pertel
Journal:  Adv Ther       Date:  2019-08-20       Impact factor: 3.845

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.